EQUITY RESEARCH MEMO
Torque Bio
Generated 5/10/2026
Executive Summary
Conviction (model self-assessment)40/100
Torque Bio is a private, Cambridge-based biotechnology company focused on RNA and gene therapy. Founded in 2018, the company leverages innovative RNA-based platforms to develop therapies for a range of diseases, though specific pipeline details are not publicly disclosed. As a private entity, Torque Bio has not disclosed funding or valuation, indicating an early or stealth-mode stage. The company operates in a competitive space with high potential but limited near-term visibility.
Upcoming Catalysts (preview)
- Q4 2026IND Filing for Lead Candidate30% success
- Q2 2026Series A Funding Announcement50% success
- Q3 2026Pipeline Update or Platform Data Release40% success
Locked sections
- · Pipeline Analysis
- · Competitive Landscape
- · Catalyst Calendar (full 12-month)
- · Bull Case
- · Bear Case
- · Counterfactual Scenarios
- · Valuation Notes
- · SEC Filing Highlights
- · Insider Activity
- · Literature Watch
- · Patent Landscape
- · Mechanism Cluster Map
- · Audio Briefing (5 min)